Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)

Stock Information for Organovo Holdings Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Organovo Holdings Inc.

Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis
Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease
Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn's and Colitis Congress
Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn's and Colitis Congress
Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results
CORRECTION - Organovo Highlights FXR314 Combination Therapy Potential and Plan

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.